Aurinia Pharmaceuticals Inc.
AUPH
$14.07
-$0.01-0.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 28.81% | 8.41% | 22.41% | 24.18% | 32.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.81% | 8.41% | 22.41% | 24.18% | 32.76% |
| Cost of Revenue | 44.25% | 34.11% | 11.99% | 7.62% | 79.93% |
| Gross Profit | 15.14% | 5.75% | 25.47% | 30.13% | 7.75% |
| SG&A Expenses | -21.00% | -38.20% | -42.10% | -57.36% | -26.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1,159.83% | -79.69% | 3,288.28% | 207.37% | -56.08% |
| Total Operating Expenses | -34.39% | -21.96% | -13.57% | -31.28% | -24.37% |
| Operating Income | 451.77% | 153.19% | 4,679.82% | 455.86% | 132.73% |
| Income Before Tax | 2,942.63% | 115.86% | 1,399.05% | 343.25% | 104.44% |
| Income Tax Expenses | -68,300.00% | -10.07% | -14.95% | 35.99% | -155.77% |
| Earnings from Continuing Operations | 14,651.15% | 119.87% | 2,879.64% | 317.17% | 105.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14,651.15% | 119.87% | 2,879.64% | 317.17% | 105.32% |
| EBIT | 451.77% | 153.19% | 4,679.82% | 455.86% | 132.73% |
| EBITDA | 278.07% | 107.98% | 469.31% | 1,738.77% | 167.17% |
| EPS Basic | 15,717.82% | 138.68% | 3,090.00% | 325.20% | 105.37% |
| Normalized Basic EPS | 132.92% | 134.31% | 829.73% | 908.33% | 162.86% |
| EPS Diluted | 14,998.02% | 130.00% | 3,090.00% | 314.48% | 105.37% |
| Normalized Diluted EPS | 131.04% | 131.34% | 811.71% | 884.72% | 160.52% |
| Average Basic Shares Outstanding | -7.20% | -7.86% | -5.90% | -3.54% | -0.52% |
| Average Diluted Shares Outstanding | -6.44% | -6.62% | -4.57% | -0.57% | 3.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |